News
-
EU Budget for 2025 Prioritizes Research, Health, Education, and Climate Action
The European Parliament has presented their draft budget demanding an EU budget for 2025 that focuses on improving
people's lives, boosting competitiveness, and addressing current challenges. MEPs are proposing a budget of nearly
€201 billion, which exceeds the European Commission's initial proposal of around €199.76 billion.
-Read more-
-
EMA publishes a reflection paper on AI in medicinal product lifecycle
The European Medicines Agency has recently published a reflection paper on the integration of artificial intelligence (AI)
throughout the lifecycle of medicinal products.
-Read more-
-
Network strategy to 2028: public consultation
The draft European Medicines Agencies Network Strategy to 2028 is available for public consultation. The deadline to comment is 30 November 2024.
-Read more-
-
Speeding up Duchenne Muscular Dystrophy therapies with a model-based clinical trial simulator
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder causing muscle deterioration. Despite advances, no cure exists, and current treatments only slow progression. To support drug development, the FDA’s Critical Path Initiative and C-Path’s Duchenne Regulatory Science Consortium (D-RSC) launched a clinical trial simulation tool. This tool optimizes trials, supporting regulatory approval and speeding new therapies to market.
-Read more-
-
PhD and postdoc opportunities - October 2024
New calls with deadlines end October - early November
-Read more-
-
Are you a clinician? Fill out the survey to share your familiarity & level of adoption of in silico medicine!
In 2021, the Virtual Physiological Human Institute conducted a clinical survey among clinicians to collect feedback regarding their knowledge, experience, and opinions about CM&S in the clinical practice. Now VPHi is realising a second and much larger survey aiming at involving doctors worldwide.
-Read more-
